CClinicalTrials.gg
RecruitingNCT05936619Updated Mar 17, 2026

MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System

An interventional study of Mind Extender (MindEx) in Paralysis; Quadriplegic, sponsored by Nader Pouratian. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Nader Pouratian · Not applicable, Interventional, and Device feasibility

Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This research study is being done to develop a novel brain-computer interface (BCI) technology that can enable severely paralyzed individuals to interact with the world through direct brain-control of a computer. This technology is named MindEx (for Mind Extender). It utilizes four implanted "chips" in the human brain from which investigators can record brain activity during subjects' thoughts and decode meaningful information from this activity to be used as control signals for a computer, a laptop, or a tablet. The use of four brain regions is a significant differentiating feature and scientific innovation of this study over much prior work in this space, that typically derived control signals from one, or sometimes two brain regions. The brain regions to be used here can allow the decode of multiple variables simultaneously, including not just moment-to-moment position, but also high-level goals, intentions, decisions, scene comprehension, and error-related signals involved in natural human behavior. The research is being done through a prospective, longitudinal, single-arm early feasibility study to examine the safety and effectiveness of using MindEx to provide the user an intuitive, efficient, and accurate ability to control multiple applications on a computer interface such as a word processor, a paint application, or to play simple video games. Such versatility could greatly improve the autonomy and quality of life of severely paralyzed individuals. Two subjects will be enrolled, each implanted with MindEx for a period of at least 53 weeks and up to 313 weeks. The study is expected to take at least one year and up to six years in total.

02

Conditions studied

  • Paralysis; Quadriplegic

Keywords

  • spinal cord injury
  • brain-computer interface
  • brain-machine interface
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Paralysis resulting from cervical spinal cord injury (SCI), brainstem stroke (ischemic or hemorrhagic), or amyotrophic lateral sclerosis (ALS)
  • Provide informed consent
  • Understand and comply with instructions, if necessary, with the aid of a translator
  • Communicate via speech or other means
  • Surgical clearance
  • Life expectancy greater than 12 months
  • Travel to study locations up to five days per week for the duration of the study
  • Caregiver monitor for surgical site complications and behavioral changes on a daily basis
  • Psychosocial support system
  • Stable ventilator status

Exclusion criteria

Exclusion Criteria:

  • Presence of memory problems
  • Intellectual impairment
  • Psychotic illness or chronic psychiatric disorder, including major depression if untreated
  • Poor visual acuity
  • Pregnancy
  • Active infection or unexplained fever
  • Scalp lesions or skin breakdown
  • HIV or AIDS infection
  • Active cancer or chemotherapy
  • Diabetes
  • Autonomic dysreflexia
  • History of seizure
  • Implanted hydrocephalus shunt
  • Prior cranioplasty
  • Other implanted devices
  • Medical conditions contraindicating surgery and chronic implantation of a medical device
  • Unable to undergo MRI or anticipated need for MRI during the study
  • Breastfeeding an infant (direct nursing or via a bottle of expressed milk)
  • Chronic oral or intravenous use of steroids or immunosuppressive therapy
  • Suicidal ideation
  • Drug or alcohol dependence
  • Planning to become pregnant, or unwilling to use adequate birth control
04

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (estimated)

Study arms

  • Experimental
    Mind Extender (MindEx)

    MindEx consists of two Neuroport Multi-Port Arrays, described in detail in the intervention description. Each NeuroPort Multi-Port Array comprises two electrode arrays implanted into human brain tissue, for a total of four electrode arrays. These will be in 1) prefrontal cortex, a brain area involved in scene comprehension, action selection, and error signaling, 2) premotor cortex, a brain area involved in planning ongoing and upcoming actions, 3) posterior parietal cortex, a brain area involved in processing sensory-to-motor transformations during movements, and 4) primary motor cortex, responsible for controlling movement. The pair of electrode arrays in each NeuroPort Multi-Port Array connect to a single percutaneous pedestal attached to the skull during a surgical procedure. Following recovery from the surgical placement, subjects will participate in study sessions up to 5 times a week. They will learn to use thought to control applications on a computer, a laptop, or a tablet.

    Device: Mind Extender (MindEx)

Interventions

  • DeviceMind Extender (MindEx)

    NeuroPort Multi-Port Arrays allow for the local recording of cerebral cortex. The Mind Extender (MindEx) system is primarily composed of two NeuroPort Multi-Port Arrays. Each Multi-Port device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D), and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array. The four arrays of the two Multi-Port device will be implanted into prefrontal cortex, premotor cortex, primary motor cortex, and posterior parietal cortex.

05

What researchers measure

Primary outcomes

  1. Continuous trajectory decoding

    A primary objective of this study is to evaluate the effectiveness of the system in providing users the ability to continuously move a cursor on a tablet/computer. The hypothesis is that trajectory readability from neural signals will be significantly greater than the level of chance. Standardized tests will be used to test this objective, and performance will be compared to the level of chance. One example of a standardized test to be used is the accuracy of continuous trajectory decoding measured by the radial-8 assessment task.

    Time frame: Six years after array implantation

  2. Incidence of intervention-related adverse events

    Serious adverse events (SAE) will be evaluated against a 1% threshold level. We will use regular inspection of the subjects' scalps to assess for breakdown, discharge, or infection, and use history and physical exam to evaluate for new symptoms, and compare to baseline assessments.

    Time frame: Six years after array implantation

  3. Competency in computer/tablet control

    An underlying hypothesis in this study is that the system will enable users the ability to control a computer/tablet interface by selecting icons. An underlying hypothesis in the study is that neural signals will enable decoding the chosen target at higher accuracy than the level of chance. Standardized tests will be used to test this objective, and performance will be compared to the level of chance. An example of a standardized test to be used is the brain-control for tablet test (BCTT) which grades the accuracy of target selection by mental fixation to the level of chance.

    Time frame: Six years after array implantation

  4. Efficacy of multiple brain regions for neural control over subsets of brain regions

    An objective of this study is to determine whether the combination of neural signals from multiple brain regions in brain-computer interface control is more advantageous than from a subset of the brain regions being tested. The hypothesis is that because the four brain regions being implanted each encode different cognitive functions, their integration will be more useful to brain-computer interface control, than any subset of these regions. This objective will be tested by standardized tests (such as those mentioned for "Competency in computer/tablet control" and "Continuous trajectory decoding") in different groups of brain regions and reported for each, such as: 1. All four brain regions: prefrontal cortex (PFC), posterior parietal cortex (PPC), dorsal premotor cortex (PMd), primary motor cortex (M1) 2. PMd,PPC, and M1 3. PPC and M1 alone

    Time frame: Six years after array implantation

Secondary outcomes

  1. Change in quality of life

    The functional change in quality of life will be evaluated through a Quality-of-Life Inventory (QOLI) administered periodically throughout the study. This is a 32-item questionnaire with a score range from 1-77, with higher scores reflecting higher satisfaction.

    Time frame: Time Frame: Annually, for six years

06

Study locations

1 of 1 sites recruiting
07

References and documents

Individual participant data

Plan to share: No — Investigators with established research programs will be eligible for data sharing. Interested investigators will be required to submit a summary of the proposed work and requested data elements. If approved by the Principal Investigator of the study, data will be shared. This data will be de-identified and coded. There is no plan to share identifiers outside the study team.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05936619
Lead sponsor
Nader Pouratian
Responsible party
Nader Pouratian (Professor & Chair, University of Texas Southwestern Medical Center) — Sponsor-investigator
First posted
Jul 10, 2023
Start date
Feb 20, 2026
Primary completion
May 30, 2030 (estimated)
Completion
Sep 1, 2031 (estimated)
Last update
Mar 17, 2026

Study contacts

Aniah Daniels, BS
Contact
aniah.daniels@utsouthwestern.edu
214-645-8003
Nader Pouratian, MD, PhD
Contact
nader.pouratian@utsouthwestern.edu
214-645-5465

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion